GlassScriptPhysician profile
Larry T Breeding
NPI 1154354033
$1,991.29
in general payments reported to CMS, 2019-2025
26 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $194 · 2021: $92.59 · 2022: $119 · 2023: $468 · 2024: $50.21 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $311.23 | 2021-2025 | Cardiomems, Aveir, Pressurewire |
| Pfizer INC. | $303.96 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $295.54 | 2019-2025 | |
| Biotronik INC. | $166.79 | 2019-2023 | Acticor 7 Vr-T Dx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.11 | 2019-2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $73.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $72.89 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $66.76 | 2019-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $61.84 | 2019-2021 | |
| Astellas Pharma US INC | $56.00 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $50.77 | 2019-2020 | |
| Esperion Therapeutics, INC. | $45.73 | 2020-2021 | |
| Lundbeck LLC | $44.57 | 2019-2020 | |
| Irhythm Technologies, INC. | $42.88 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $41.72 | 2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $31.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.77 | 2019-2021 | |
| Terumo Medical Corporation | $29.78 | 2024 | Tr Band, Angio-Seal |
| Novo Nordisk INC | $28.48 | 2025 | Wegovy |
| Bracco Diagnostics INC. | $23.39 | 2019 | |
| Philips North America LLC | $21.53 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.67 | 2025 | |
| Genzyme Corporation | $14.51 | 2019 | |
| Amgen INC. | $13.92 | 2023 | Repatha |
| United Therapeutics Corporation | $13.50 | 2019 | |
| Amarin Pharma, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Breeding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.